Lilly Unveils Groundbreaking AI Factory for Drug Discovery with NVIDIA's DGX SuperPOD
Ted Hisokawa Oct 29, 2025 08:38
Lilly has launched the largest AI factory in the pharmaceutical sector, leveraging NVIDIA's DGX SuperPOD to revolutionize drug discovery and personalized medicine.
Lilly has announced the deployment of the world's largest and most powerful AI factory specifically designed for drug discovery, utilizing NVIDIA's DGX SuperPOD technology, according to NVIDIA's blog. This advanced AI infrastructure is set to transform the pharmaceutical landscape by significantly shortening drug development timelines and enhancing personalized medicine strategies.
Revolutionizing Pharmaceutical Research
The AI factory, equipped with over 1,000 NVIDIA Blackwell Ultra GPUs, aims to support cutting-edge scientific research through the use of foundation models and agentic AI. This state-of-the-art facility will enable the training of large-scale biomedical models, facilitating breakthroughs in genomics and molecular design at an industrial scale.
Lilly's AI-powered facility is expected to compress drug discovery timelines, leading to faster and more efficient development of new treatments. The AI models developed will be accessible via Lilly TuneLab, an AI and machine learning platform that provides biotech companies with access to Lilly's proprietary drug discovery data valued at $1 billion.
Enhancing Drug Discovery and Precision Medicine
With the integration of NVIDIA's AI architecture, Lilly scientists can analyze entire genome sequences, predict patient outcomes, and explore various biochemical possibilities. This capability is anticipated to expedite the development of more personalized and targeted medicines.
Diogo Rau, Lilly's Executive Vice President and Chief Information and Digital Officer, emphasized the synergy between science and technology in achieving large-scale treatment solutions. By harnessing the power of AI, Lilly aims to deliver treatments to millions of patients more efficiently than ever before.
AI in Biomanufacturing and Supply Chain Optimization
The AI factory is set to enhance Lilly's biomanufacturing capabilities, improving the reliability of medication supply chains. Using technologies like NVIDIA Omniverse and RTX PRO Servers, Lilly can create digital twins of its manufacturing lines, allowing for the optimization of supply chains and the acceleration of quality assurance processes.
Additionally, Lilly plans to deploy intelligent robotics for quality inspection and transport of goods, ensuring continuous production and minimizing downtime. This integration of AI-driven solutions is aimed at maintaining peak performance and optimizing production systems.
Economic Growth and Industry Leadership
Lilly's new AI factory underscores its position as a leader in AI-driven pharmaceutical innovation. The facility, part of a broader $50 billion initiative to expand U.S. manufacturing and R&D efforts, is expected to create thousands of high-wage jobs and further strengthen the company's global leadership in the field.
By converting proprietary data into actionable intelligence, Lilly aims to enhance patient care while contributing to economic growth and reinforcing U.S. leadership in advanced manufacturing and regulated industries. Thomas Fuchs, Lilly's Chief AI Officer, highlighted the transformative potential of AI in medicine design and development, marking a new era for the pharmaceutical industry.
Image source: Shutterstock.jpg)